argenx SE vs Johnson & Johnson
ARGX vs JNJ — side-by-side comparison from reported financials. ARGX leads 5, JNJ leads 5 of 10 comparable metrics.
argenx SE
ARGX · Healthcare
$825.03+0.78%Strong
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
| Metric | ARGX | JNJ |
|---|---|---|
| Price | $825.03 | $261.79 |
| Market cap | $51.9B | $631B |
| Revenue (TTM) | $4.24B | $97.9B |
| Revenue growth | +116.2% | +5.6% |
| Net margin | 30.5% | 21.5% |
| Free cash flow | $970M | $22.2B |
| Net cash (debt) | $5.14B | ($27.8B) |
| 1-year price return | +2.5% | +37.0% |
| P/E | 20.1 | 29.9 |
| P/E vs own history (cheap-side %) | 92% | 16% |
| Dividend yield | — | 2.00% |
| Return on equity | 22% | 26% |
| Altman Z-score | 21.86 | — |
| CV checks passed | 8 of 10 | 10 of 10 |
| Employees | 1,863 | 140,800 |
Full résumé-style profiles: ARGX CV · JNJ CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.